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Tuberous sclerosis complex (TSC) is an autosomal-
dominant disease that is caused by mutations in
either the TSC1 or TSC2 gene. Smooth muscle-like
cells (ASMs) were isolated from an angiomyolipoma
of a patient with TSC. These cells lacked tuberin,
were labeled by both HMB45 and CD44v6 antibod-
ies , and had constitutive S6 phosphorylation. The
cells bear a germline TSC2 intron 8-exon 9 junction
mutation, but DNA analysis and polymerase chain
reaction amplification failed to demonstrate loss of
heterozygosity. Testing for an epigenetic alteration,
we detected methylation of the TSC2 promoter. Its
biological relevance was confirmed by tuberin ex-
pression and a reduction in HMB45 labeling and S6
constitutive phosphorylation after exposure to the
chromatin-remodeling agents , trichostatin A and
5-azacytidine. These cells were named TSC2/meth
ASMs. Their proliferation required epidermal growth
factor in the medium as previously described for
TSC2/ ASMs. Blockade of epidermal growth factor
with monoclonal antibodies caused the death of
TSC2/meth ASMs. In addition, rapamycin effectively
blocked the proliferation of these cells. Our data show
for the first time that methylation of the TSC2 pro-
moter might cause a complete loss of tuberin in
TSC2 cells , and that the pathogenesis of angiomyolipo-
mas might also originate from epigenetic defects in
smoothmuscle cells. Additionally, the effect of chroma-
tin-remodeling agents in these cells suggests a further
avenue for the treatment of TSC as well as lymphangio-
leiomyomatosis. (Am J Pathol 2009, 174:2150–2159; DOI:
10.2353/ajpath.2009.080799)
Tuberous sclerosis complex (TSC) is an autosomal-dom-
inant disease characterized by hamartomas, in a wide
array of tissues and organs, such as brain, kidney, skin,
heart, and lungs.1 Abdominal angiomyolipomas are of-
ten present in TSC patients; they may cause life-threat-
ening hemorrhages and in such conditions their surgi-
cal resection is required.2 The tumor suppressor
genes, TSC1 and TSC2, are associated with the devel-
opment of TSC, and mutations in either gene are respon-
sible for familial and sporadic forms of the disease.1 The
TSC2 gene is located on chromosome 16p13 whereas
TSC1 on chromosome 9q34.3,4 Hamartin, the TSC1 gene
product, stabilizes tuberin, the TSC2 gene product,
through binding with it, thereby preventing tuberin from
ubiquitination and degradation.5 Tuberin acts as a GT-
Pase-activating protein to regulate Rheb function through
the conversion of Rheb from the active GTP-bound form
to the inactive GDP-bound form.6,7 Active Rheb activates
mTOR, and the up-regulation of the TSC/mTOR signaling
pathway leads to increased protein synthesis, cell prolif-
eration, and ultimately to tumorigenesis.8
TSC occurs because of a germline mutation in either
TSC1 or TSC2. In most hamartomas, TSC follows a second
hit inactivating the wild-type allele. The loss of heterozygos-
ity (LOH) in TSC1 or TSC2 has been documented in angio-
myolipomas (AMLs), cardiac rabdomiomas, and lym-
phangioleiomyomatosis (LAM) cells, but it has only rarely
been found in cerebral cortical tubers and skin lesions.9–11
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Therefore, it is not clear whether inactivation of both alleles
is the necessary step for hamartoma pathogenesis. Various
explanations have been raised to define the inability to find
a second somatic event in TSC lesions, and the failure to
demonstrate such events has been attributed to either dif-
ferent genetic and epigenetic deficits in TSC genes or cell
heterogeneity in TSC hamartomas.12,13 DNA methylation is
an epigenetic change that induces chromatin modifications
and repression of transcription via a methyl CpG binding
protein MeCP2, and recruitment of a Sin3A/HDAC co-re-
pressor complex.14,15 Twenty-four hamartomas from 10 pa-
tients were analyzed by Niida and colleagues11 for second-
hit mutations by promoter methylation of TSC2, but no
evidence of such inactivation of the second allele was
detected.
Here we report the isolation and characterization of a
homogenous population of smooth muscle-like cells from
AML cells (ASM cells) of a TSC2 patient. The ASM cells
were mostly positive for HMB4516 and CD44v6,17 that are
markers of TSC and LAM cells, and showed a germline
TSC2 intron 8-exon 9 junction mutation with no LOH.
However, tuberin was undetectable by immunochemistry
and Western blotting. We found that these cells were
methylated in the TSC2 promoter, and the involvement of
methylation in the inhibition of TSC2 gene was confirmed
by the cellular expression of tuberin after exposure to the
chromatin remodeling agent, trichostatin A. Thus, ASM
cells were named TSC2/meth ASM cells. The prolifera-
tive, morphological, and biochemical characteristics of
TSC2/meth ASM cells were very similar to TSC2/
smooth muscle cells with LOH that we previously isolated
from an AML of a female TSC2 patient (TSC2/ ASM
cells).18,19 The growth of TSC2/meth ASM cells requires
the addition of epidermal growth factor (EGF) to the culture
medium, whereas the exposure to specific monoclonal an-
tibody raised against EGFR causes the blockade of prolif-
eration and their death. Our data show for the first time that
the methylation of the TSC2 promoter might cause loss of
tuberin in TSC2 cells, and that such epigenetic alteration of
smooth muscle cell function may underlie their abnormal
growth and likely lead to AML development.
Materials and Methods
Establishment of the Angiomyolipoma Culture
The renal angiomyolipoma sample was obtained during
total nephrectomy from a 36-year-old man with a history
of TSC who had given his informed consent according to
the Declaration of Helsinki. The cells were obtained as
shown in Lesma and colleagues.18 Briefly, the tumor
tissue was manually dissociated using collagenase type
II (Sigma, St. Louis, MO) by means of repetitive pipetting.
The collagenase was neutralized with a serum-containing
medium (50:50 mixture of Dulbecco’s Eagle’s medium/
Ham F12; Euroclone, Paignton, UK) supplemented with
hydrocortisone (2  107 mol/L) (Sigma-Aldrich, St.
Louis, MO), EGF (10 ng/ml) (Sigma-Aldrich), sodium se-
lenite (5 108 mol/L) (Sigma-Aldrich), insulin (25 g/ml)
(Sigma-Aldrich), transferrin (10 g/ml) (Sigma-Aldrich),
ferrous sulfate (1.6  106 mol/L) (Sigma-Aldrich), and
15% fetal bovine serum (Euroclone) as indicated by Ar-
biser and colleagues.20 Vascular smooth muscle-like
cells (VSMCs) and A549 cells were grown in Dulbecco’s
modified Eagle’s medium supplemented with fetal bovine
serum 10%.
Cell Immunofluorescence Microscopy
The cells were cultured on glass slides, permeabilized
with Cytoskelfix (Cytoskeleton, Denver, CO) and dried in
air. The primary antibody against -actin (1:100, Sigma-
Aldrich), vimentin (1:70; Santa Cruz Biotechnology, Santa
Cruz, CA), S100 (1:8000; DAKO, Carpinteria, CA) keratin
8/18 (1:100; New Marker, Fremont, CA), HMB45 (1:100,
DAKO), CD44v6 (1:100; Invitrogen, Carlsbad, CA),
hamartin (1:100, Santa Cruz Biotechnology), tuberin (C-
20) (1:100, Santa Cruz Biotechnology) were applied over-
night at 4°C. The samples were incubated for 3 hours at
room temperature with fluorescein isothiocyanate-conju-
gated anti-mouse antibody (Alexa, Eugene, OR) for -ac-
tin, HMB45, and keratin 8/18, with fluorescein isothiocya-
nate-conjugated anti-goat antibody (Alexa) for vimentin
and hamartin, with rhodamine-conjugated anti-rabbit an-
tibody (Alexa) for tuberin.
HMB45 positivity was evaluated by immunofluores-
cence. Cells were incubated for 72 hours with trichostatin
(3.3 mmol/L). HMB45 labeling was defined as strong (),
and negative (). Quantitation of HMB45 intensity was
achieved with a confocal microscopy (TCS-SP2; Leica,
Wetzlar, Germany) and analyzed by Leica confocal soft-
ware using the profile through stack/series methods as
follows: 30 equal polygonal areas covering the cells were
randomly selected on each image. The fluorescence in-
tensity values of the selected cells were quantified and
the mean and the SD of the data were calculated by
GraphPad software (La Jolla, CA). The level of statistical
significance was determined by Student’s t-test.
Western Blotting
The cells were lysed in lysis buffer (5 mmol/L ethylenedia-
minetetraacetic acid, 100 mmol/L deoxycholic acid, 3%
sodium dodecyl sulfate), boiled, electrophoretically run
on a 10% sodium dodecyl sulfate-polyacrylamide gel
electrophoresis gel, and transferred to nitrocellulose
membranes (Amersham, Arlington Heights, IL). After be-
ing blocked at room temperature for 3 hours with 5% dry
milk (Merck, Darmstadt, Germany), the membranes were
incubated overnight at 4°C with antibodies against tu-
berin, phospho-tuberin (Thr1462) (1:1000; Cell Signaling,
Beverly, MA), hamartin (a gift from Dr. Mark Nellist and
Dr. Dicky Halley, Erasmus University, Rotterdam, The
Netherlands), phospho-Akt (Ser473) (1:1000, Cell Sig-
naling), phospho-S6 ribosomal protein (Ser235/236) (1:
1000, Cell Signaling), S6 ribosomal protein (1:1000, Cell
Signaling), phospho-extracellular signal-regulated kinase
(Erk) (Thr202/Tyr204) (1:1000, Cell Signaling), Erk (1:
1000; Cell Signaling), EGF receptor (1:200; Santa Cruz
Biotechnology), -actin (1:10,000, Sigma-Aldrich), p53
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(1:100, Santa Cruz Biotechnology), p21 (1:1000, Cell Sig-
naling). The membranes were washed and incubated for
1 hour with anti-rabbit antibody (1:10,000; Chemicon,
Temecula, CA). The reaction was revealed using the
SuperSignal West Pico Chemiluminescent Substrate
(Pierce, Rockford, IL). Densitometric analysis was per-
formed by Kodak MJ project program (Eastman-Kodak,
Rochester, NY). Data were expressed as optical density.
Mutation Study
The DNAs were extracted from peripheral blood, angio-
myolipoma, and isolated cultured cells using the Wizard
Genomic DNA purification kit (Promega, Madison, WI). All
of the exons and intron-exons junctions of TSC1 and
TSC2 from the genomic DNAs were amplified by means
of standard polymerase chain reaction (PCR) and de-
scribed primers.21 The sequencing reactions were per-
formed as previously reported by Lesma and col-
leagues18 and repeated at least twice.
LOH Analysis
The panel of microsatellite markers near the TSC2 locus on
chromosome 16p13.3 consisted of D16S525, D16S3024,
D16S3394, D16S291, D16S664, and D16S663. The 5
sense primers were labeled with 6-FAM fluorescent dyes
(M-Medical, Cornaredo, Italy). The primer sequences were
obtained from the Genome Database (http://www.ncbi.nlm.
nih.gov/). Microsatellite orientation and position were ob-
tained from UCSC Genome Browser (http://genome.ucsc.
edu/cgi-bin/hgGateway). LOH was analyzed as previously
described in Lesma and colleagues.18
Methylation Assays
The methylation status of the TSC2 and ZFX promoter
regions was analyzed by PCR using as template the
genomic DNA previously digested with the methylation-
sensitive enzyme HpaII and with its isoschizomer MspI,
insensitive to methylation (New England Biolabs, Beverly,
MA). The primers used for amplifications spanned sev-
eral methylation-sensitive restriction sites (seven for
TSC2 gene) in the 5 of the tested genes. The UCSC
Browser (http://genome.ucsc.edu/cgi-bin/hgGateway) and
the CpG island searcher (http://cpgislands.usc.edu/) were
consulted to identify TSC2 promoter region and CpG island.
The primers used to TSC2 promoter analysis were
sense 5-atgccgctaccggaagtgc-3 (chr16: 2037,961-
2037,979, UCSC Genome Browser) and antisense 5-
tggtctagagagctctctact-3 (chr16:2038,391-2038,371,
UCSC Genome Browser). After denaturation at 94°C for 5
minutes, 35 cycles of PCR were done; each cycle con-
sisted of 45 seconds at 95°C, 45 seconds at 54°C, and 45
seconds at 72°C. ZFX primers and methods are fully
described in Gilbert and Sharp.22
To quantify the methylation levels of TSC2 promoter,
pyrosequencing technology was used to analyze the
same region studied by methylation-sensitive digestion
assay. The bisulphite conversion of genomic DNA (1 g)
was obtained using EZ DNA methylation kit (Zymo Re-
search, Orange, CA). After bisulphite treatment, PCR was
performed in a final volume of 50 l with 2.5 U of Promega
Go-Taq Hot Start Polymerase (Promega). The primer se-
quences for modified sequences are: forward primer 5-
ttygttagagggyggtatagaat-3 (chr16: 2037,899-2037,921,
UCSC Genome Browser) and biotinylated reverse primer
5-acactacraaatccrcctctc-3 (chr16: 2038,141-2038,121,
UCSC Genome Browser). The PCR conditions were: step
1: 95°C, 2 minutes; step 2: 95°C, 30 seconds; step 3:
61.2°C decrease 0.5°C per cycle, 30 seconds; step 4:
72°C, 30 seconds; step 5: repeat steps 2 to 4 14 more
times; step 6: 95°C, 30 seconds; step 7: 54°C, 30 sec-
onds; step 8: 72°C, 30 seconds; step 9: repeat steps 6 to
8 31 more times; step 10: 72°C, 5 minutes. Forty l of
PCR product were used for pyrosequencing assay using
the sequencing primers 5-atyggaagtgygggt-3 (chr16:
2037,969-2037,983, UCSC Genome Browser).
Pyrosequencing reactions were performed in the PSQ
HS 96 system (Biotage, Uppsala, Sweden) by using Pyro
Gold reagent kits (Biotage). Methylation was quantified
using Pyro Q-CpG Software (Biotage), which calculates
the ratio of converted Cs (Ts) to unconverted Cs at each
CpG and expresses this as a percentage of methylation.
To assess the methylation pattern in normal condition we
analyzed different normal DNA from peripheral blood
lymphocytes.
Evaluation of Cell Growth and Proliferation
The proliferation growth factor dependence of the smooth
muscle-like cells and VSMCs were assayed in the pres-
ence or absence of EGF (10 ng/ml) or by replacing EGF
with insulin-like growth factor 1 (IGF-1) (50 ng/ml), by
counting the cells after 4, 7, 17, 21, and 25 days of culture
in a Neubauer chamber. Anti-EGFR antibody (clone 225;
Calbiochem, Darmstadt, Germany), and IGF-1R (clone
IR3, Calbiochem) were added at a concentration of 5
g/ml to the complete medium, and cell proliferations
were evaluated after 4, 7, 17, 21, and 25 days of culture.
Each data point of the proliferation experiments is the
mean of four independent experiments.
Cell Treatments
Trichostatin A (Sigma-Aldrich) was incubated for 72
hours at the concentration of 3.3 mmol/L. 5-Azacytidine
(Sigma-Aldrich) was incubated for 96 hours at the con-
centration of 1 or 10 mol/L. In the Western blotting
experiments to study S6 and Erk phosphorylation, cells
were incubated with rapamycin (1 ng/ml) or anti-EGFR
antibody (5 g/ml) for 24 or 48 hours. Cells were incu-
bated for 2 hours with IGF-1 (50 ng/ml) with or without
LY294002 (20 mol/L) (Sigma).
The action of rapamycin (Rapamune-Sirulimus; Wyeth
Europa, Maidenhead, UK) was evaluated by adding 1
ng/ml and 5 ng/ml to the TSC2/meth cells at plating time
and 3 hours after plating, and measuring cell proliferation
after 5, 8, and 10 days or evaluating the apoptotic effect
by terminal dUTP nick-end labeling (TUNEL) analysis
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after a 10-day incubation. For TUNEL analysis VSMCs
were incubated with staurosporin (100 mmol/L) for 1 hour
30 minutes.
TUNEL Analysis
Apoptotic cells were examined by TUNEL analysis using
an in situ cell death DeadEnd colorimetric TUNEL system
(Promega) following the manufacturer’s instruction.
Briefly, cells were fixed for 25 minutes in 4% paraformalde-
hyde, washed twice in PBS for 5 minutes, permeabilized in
0.2% Triton X-100 for 5 minutes, and washed twice in PBS
for 5 minutes. Slides were incubated with rTdT reaction mix
for 1 hour at 37°C, then endogenous peroxidases were
blocked with 0.3% hydrogen peroxide for 5 minutes at room
temperature. After incubation with streptavidin horseradish
peroxidase, apoptotic cells were localized using 3,3-dia-
minobenzidine tetrahydrochloride. The number of TUNEL-
positive cells was counted and the data presented are
mean of the percentage of TUNEL-positive cells.
Statistical Analysis
The data are expressed as mean values  SEM, and were
statistically analyzed using Student’s t-test; significance is
indicated for P values of *0.05, **0.01, and ***0.001.
Results
Cellular Characterization
From the angiomyolipoma of a male TSC patient, a ho-
mogenous cellular population was isolated and cultured
in monolayers. The characteristic elongated shape
strongly resembled TSC2 smooth muscle (TSC2/ ASM)
cells isolated from an angiomyolipoma of a female TSC2
patient and previously described by our group.18 The
majority of these isolated cells were strongly labeled by
-actin antibody, the marker for smooth muscle cells
(Figure 1), whereas the lack of detection of vimentin,
keratin 8-18, and S100 suggested that fibroblasts, epi-
thelial-like cells, or adipocytes were absent from this
cellular population (Figure 1). The angiomyolipoma-de-
rived smooth muscle (ASM) cells were also labeled by
the typical markers of TSC and LAM cells, HMB45 anti-
body,16 and CD44v6 antibody17 (Figure 1).
Figure 1. Immunocytochemical characterization of TSC angiomyolipoma-de-
rived cells. Characterization was performed using a panel of antibodies related to
the AML cellular constituents. TSC cells were positively labeled by -actin
antibody, a marker of smooth muscle cells. Cells were negative for S100, a
marker of lipid-containing cells; vimentin, a marker of fibroblasts; and keratin
8-18, a marker for epithelial-like cells. Antibodies to HMB45 and CD44v6,
markers of TSC and LAM cells, positively immunolabeled these TSC cells. Scale
bars  50 m.
Figure 2. Genetic and biochemical analysis of TSC angiomyolipoma-derived
cells. A: The shown mutation was determined by direct sequence analysis of
blood from a control and the TSC patient, and the isolated cells. The mutation
site is indicated by a vertical arrow. Cell sequencing revealed the mutation in
TSC2 intron 8-exon 9 junction mutation (c.867-2AG). B: The expression of
tuberin and hamartin in the ASM cells was determined by Western blotting
and immunofluorescence. Tuberin was undetectable in the purified ASM
cells and TSC2/ ASM cells, whereas it was expressed in VSMCs and A549
cells. Hamartin was expressed in all cell types. The blots are representative of
four separate experiments. The immunocytochemical staining is referred
only to the purified ASM cells. Scale bars  50 m.
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Mutation Analysis
A germline TSC2 intron 8-exon 9 junction heterozygous
mutation (c.867-2AG) was detected by DNA sequenc-
ing in patient blood and angiomyolipoma (data not
shown) and in angiomyolipoma-derived ASM cells (Fig-
ure 2A). The LOH of these ASM cells was tested by
means of PCR amplification, using a panel of microsat-
ellite markers near the TSC2 locus on chromosome
16p13.3, but we failed to detect LOH (data not shown).
On the other hand, these newly isolated ASM cells lacked
tuberin as immunofluorescence and Western blotting
failed to reveal any positive reactivity to specific antibod-
ies. This negative result can be compared with what
observed in TSC2/ ASM cells, whereas VSMCs and
A549 cells, used as control, expressed tuberin, as ex-
pected (Figure 2B). Differently, hamartin was present at
comparable levels in all tested cells and -actin was
evaluated as protein control (Figure 2B).
Methylation of the TSC2 Promoter Region
The absence of LOH and the lack of tuberin expression in
ASM cells led us into assessing whether the Knudson sec-
ond hits could be epigenetic. We analyzed the DNA meth-
ylation of the CpG island within the TSC2 promoter region,
using methylation-sensitive digestion with HpaII restriction
enzyme. Methylation (presence of PCR amplification after
HpaII digestion) of the promoter in ASM cells was found
while normal VSMCs cells were unmethylated (absence of
PCR amplification after HpaII digestion) (Figure 3A).
To control the enzyme cleavage efficiency we chose two
different approaches. In the first case, it was used the
Figure 3. DNA methylation in TSC2 promoter and
effect of chromatin remodeling agents, trichostatin
A (TSA) and 5-azacytidine (5-AZA). A: The lack of
tuberin in TSC2 ASM cells was evaluated by DNA
methylation of the CpG island within the TSC2 and
ZFX promoter regions, using methylation-sensitive
digestion with HpaII restriction enzyme and its
isoschizomer MspI. The determination was per-
formed three times. Methylation occurs at the pro-
moter site in the TSC2 ASM cells (left) and AML
tissue (right). B: Pyrograms indicating the per-
centage of methylation (light blue boxes) of three
explicative CpGs within TSC2 promoter region of
the normal control (left) and TSC2/meth ASM cells
(right). These CpGs are a part of the methylation
sites analyzed by methylation-sensitive digestion
assay. C: After incubation with TSA (3.3 mol/L)
for 72 hours (left) or 5-azacytidine (5-AZA) (1 and
10 mol/L) for 96 hours (right), tuberin and phos-
pho-tuberin (Thr1462) expressions were pro-
moted in TSC2/meth ASM cells as evaluated by
Western blotting. The phosphorylated form was
detectable only after 5-AZA incubation. As ex-
pected TSA did not have any effect on tuberin
expression in TSC2/ ASM cells. Experiments
were done four times. The expression of tuberin
induced by treatments with TSA or 5-AZA was also
confirmed by immunocytochemical staining. D:
Effect of trichostatin A on HMB45 labeling of
TSC2
/meth
ASM cells. The positive cells are indi-
cated with , and the negative with . The expo-
sure to trichostatin A reduced HMB45 labeling very
significantly. Mean values  SEM. Significant dif-
ferences (***P  0.001) versus control were eval-
uated by Student’s t-test. Scale bars  50 m.
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digestion with MspI, an isoschizomer of HpaII that, unlike
HpaII, can cleave the sequence when the internal C of
the restriction site CCGG is methylated. In the second case
the cleavage efficiency was tested with the amplification of
ZFX promoter, which is always unmethylated. As expected,
we found a complete DNA digestion in both controls, and
this resulted in no PCR amplification in all samples (Fig-
ure 3A). In addition we observed the TSC2 promoter
methylation in the original AML tissue, although there was
a reduced extent probably because of the heterogeneity
of AML (Figure 3A). To confirm the above reported qual-
itative methylation data we performed the pyrosequenc-
ing quantitative assay on the same promoter regions
analyzed with methylation-sensitive digestion. This
method allows us to reveal quantitatively the methylation
of all CpGs position. In normal samples TSC2 resulted
demethylated in all CpGs analyzed (Figure 3B). In the
TSC2/meth ASM cells, consistently with our previous re-
sults, we found a promoter methylation pattern indicating
an epigenetic silencing. The low methylation levels (29%,
6%, 6%) obtained with the pyrosequencing analysis were
indicative of methylation of only one allele.
In the isolated ASM cells the epigenetic silencing of
TSC2 was confirmed by transcriptional reactivation with
consequent tuberin expression after treatment with the
histone deacetylase inhibitor trichostatin A for 72 hours or
with the DNA methylase inhibitor 5-azacytidine for 96
hours (Figure 3C). Trichostatin A and 5-azacytidine are
chromatin-remodeling agents able to reactivate genes
epigenetically silenced.23–25 After the demonstration of
the DNA methylation of the CpG island, the angiomyoli-
poma-derived ASM cells were named TSC2/meth ASM
cells, and thereafter we shall use this name. After 5-aza-
cytidine exposure we monitored for a week the prolifera-
tion of TSC2/meth cells; the rate of proliferation was
comparable with control. With trichostatin A the overpro-
liferation was eliminated (data not shown).
To evaluate the effects of trichostatin A-induced tu-
berin expression on the phenotype of TSC2/meth ASM
cells, gp100 expression was quantified by exposure to
HMB45 antibody, a marker of TSC and LAM cells.16,18
After 72 hours of trichostatin A exposure, the labeling was
greatly reduced. HMB45 reactivity was quantified as pos-
itive () or negative (). Normally, 	70% of untreated
TSC2
/
ASM cells were strongly labeled by HMB45 (Fig-
ure 3C), whereas after incubation with trichostatin A,
HMB45-labeled cells were reduced to 45%, and the neg-
ative ones increased from 30 to 55% (Figure 3D).
Effect of Trichostatin A on TSC2/meth ASM Cell
Phenotype
To further investigate the effects of trichostatin A in
TSC2/meth ASM cells, we evaluated S6 and Erk phos-
phorylation. After a 72-hour incubation with trichostatin A
there was a reduction of S6 and Erk phosphorylation in
TSC2/meth ASM cells (Figure 4). This was not observed
in TSC2/ ASM cells (Figure 4). The expression of S6
and Erk were not changed by trichostatin A in both cell
lines (Figure 4). Thus the induced expression of tuberin
by trichostatin A exposure correlated with down-regula-
tion of the constitutive phosphorylation of S6. As ex-
pected, trichostatin A led to a slowing proliferation rate
even within these 72 hours (data not shown).
Role of PI3K Pathway in TSC2/meth ASM Cells
We had previously shown that the specific inhibitor
LY294002 was unable to inhibit PI3K in TSC2/ ASM
cells.26 Here we report that a similar phenomenon was
also present in TSC2/meth ASM cells (Figure 5). Addition
of IGF-1 increased Akt and PTEN phosphorylation without
affecting constitutive S6 phosphorylation and the co-in-
cubation with LY 294002 failed to modify the extent of
both basal and IGF-1-mediated phosphorylations (Figure
5). After incubation with trichostatin A for 72 hours, the
LY294002 addition was able of reduce the extent of both
basal and IGF-1-stimulated Akt phosphorylation in
TSC2/meth ASM cells (Figure 5). In this latter condition,
also the IGF-1-promoted increase of S6 phosphorylation
was inhibited by LY294002 (Figure 5).
Regulation of Growth of TSC2/meth ASM Cells
We have detected EGFR by Western blotting analysis of
TSC2/meth ASM cells, and the level of expression is com-
parable with that of TSC2/ ASM cells, vascular smooth
muscle cells (VSMCs) and A549 cells (Figure 6A, inset).
Also, the proliferation of TSC2/meth ASMcells required EGF
addition to the culture medium and the substitution with
another growth factor, such as IGF-1, could not substitute
for EGF-proliferative action (Figure 6A). Moreover, the expo-
sure to anti-EGFR and anti-IGF-1R antibodies reduced the
proliferation and caused the progressive loss of TSC2/meth
ASM cells. The rate of proliferation of the TSC2/meth ASM
cells in presence or absence of EGF and the ability of
anti-EGFR or anti-IGF-1R antibodies to kill them are
Figure 4. Effect of trichostatin A (TSA) (3.3 mol/L) incubation (72 hours)
on S6 and Erk phosphorylation in TSC2/ and TSC2/meth ASM cells. In
TSC2/meth ASM cells, trichostatin A markedly reduced the constitutive phos-
phorylation of S6 (Ser235/236) and also Erk (Thr202/Tyr204) phosphoryla-
tion. No effect by trichostatin A was observed in TSC2/ ASM cells. The
blots are representative of three independent experiments. These data were
confirmed by the densitometric analysis. Mean values  SEM. Significant
differences (***P  0.001) versus control were evaluated by Student’s t-test.
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comparable with those observed for TSC2/ ASM
cells (Figure 6B).
Rapamycin was applied at 1 and 5 ng/ml at time of
plating or 3 hours later. Rapamycin significantly reduced
the rate of cell proliferation either when applied at plating
time or 3 hours after plating causing a significant loss of
cells at the concentration of 5 ng/ml (Table 1). The per-
centage of attached cells was 80  1,6% and 96  0.7%
at 3 and 16 hours after plating, respectively. The effect of
the delayed addition is different to what was observed in
TSC2/ ASM cells, which were affected by rapamycin
only when the drug was applied at plating time.26
Effect of Anti-EGFR Antibody and Rapamycin
on S6 and Erk Phosphorylation in TSC2/meth
ASM Cells
The cellular effects of anti-EGFR antibody on TSC2/meth
ASM cell proliferation were also evaluated biochemically.
It is well known that TSC protein abnormalities may lead
to dysregulation of mTOR activity with increased p70 S6
kinase activity, and, as expected, TSC2/meth ASM cells
presented constitutive phosphorylation of S6. After 24 or
48 hours of incubation with rapamycin or anti-EGFR an-
tibody the extent of such phosphorylation was reduced
without changes in S6 expression (Figure 7). Because the
Erk signaling pathway is activated by EGF and is a major
contributor to cellular growth, we have studied the phos-
phorylation of this kinase after exposure to anti-EGFR
antibody or rapamycin. The extent of Erk phosphorylation
was reduced by anti-EGFR, mainly after a 48-hour incu-
bation while the Erk levels were unchanged (Figure 7).
The effect of rapamycin on Erk phosphorylation was,
however, rather minor (Figure 7). The rapamycin-medi-
ated reduced ability of TSC2/meth cells to proliferate was
not accompanied by enhancement of apoptosis. Rapa-
mycin was added to the medium at 1 or 5 ng/ml at plating
time or 3 hours after plating for 10 days; this did not
change the expression of p21 and p53 (Figure 8); more-
over, the number of TUNEL-positive cells remained com-
parable with control untreated cells (Table 2). Differen-
tially, 57.3% of VSMCs, used as control, underwent
Figure 5. Effect of trichostatin A (TSA) on the PI3K pathway. TSC2/meth
ASM cells were incubated with or without trichostatin A (3.3 mol/L) for 72
hours and then with IGF-1 (50 ng/ml) and LY294002 (LY) (20 mol/L) for 2
hours. IGF-1 exposure of TSC2/meth ASM cells induced Akt (Ser473) and
PTEN (Ser380/Thr382/Thr383) phosphorylation without affecting S6 (Ser235/
236) phosphorylation. The co-incubation with IGF-1 and PI3K inhibitor,
LY294002, did not modify the extent of phosphorylation of Akt, PTEN, and
S6. The expression of Akt and S6 was unaffected by any treatment. After
trichostatin A exposure, LY290042 was capable of antagonizing IGF-1-medi-
ated and basal phosphorylation of both Akt and S6 whereas the phosphor-
ylation of PTEN was unaffected as reported for TSC2/ ASM cells after
retroviral transfection of the TSC2 gene.26 The expression of Akt and S6
proteins was unaltered. The blots are representative of four independent
experiments. These data were confirmed by the densitometric analysis
(graphs at the right). Mean values  SEM. Significant differences (*P  0.05;
**P  0.01; ***P  0.001) versus control were evaluated by Student’s t-test.
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Figure 6. Evaluation of EGF and IGF-1 role in TSC2/meth ASM proliferation.
Cells were counted after 4, 7, 17, 21, and 25 days of culture. A: The growth
and proliferation of TSC2/meth ASM cells required the addition of EGF (10
ng/ml) in the culture medium; IGF-1 (50 ng/ml) failed to promote any
increase in cell number. The treatment with either anti-EGFR or anti-IGF-1R
antibodies limited the growth rate in the early days of drug exposure and
then started to die. Experiments were done four times. Inset: Expression of
EGF receptor (EGFR). B: Comparison of the proliferation of the TSC2/ (full
line) and TSC2/meth (dashed line) ASM cells in presence or absence of EGF,
and with anti-EGFR or anti-IGF-1R antibodies. The beginning of the treat-
ment was considered 100% of the percentage of the cells. The growth rate of
the two cell lines was similar. Experiments were done three times each. Mean
values  SEM. Significant differences (***P  0.001) versus control were
evaluated by Student’s t-test.
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apoptosis after exposure to 100 mmol/L staurosporin for
1 hour and 30 minutes (Table 2).
Discussion
TSC is a tumor suppressor gene disorder associated with
benign and malignant tumors, and angiomyolipomas are
the most common renal tumors. They are composed of
smooth muscle, fat, and vascular cells.27 Tuberin is the
TSC2 gene product; it functions as a renal tumor sup-
pressor gene and regulates cell growth and cell cycle
progression.28 The lack of tuberin may lead to abnormal
cell proliferation.29 LOH in TSC cells occurs in 60% of the
angiomyolipomas of women with sporadic LAM.30 We
have previously reported the isolation and the character-
ization of TSC2/ ASM cells from an angiomyolipoma
with a mutation in exon 18 consisting of a stop codon
associated to LOH of TSC2 locus.18 The lack of tuberin
appears to be strictly related to their EGF requirement for
growth.18 In the current study we report that the lack of
tuberin in TSC2 cells may also be caused by an epige-
netic silencing such as the methylation of the TSC2 gene
promoter.
Blood and ASM cells of a TSC2 patient bear the so-
matic mutation of TSC2 gene in intron8-exon9 junction
(867-2AG), on the other hand the newly purified angio-
myolipoma cells did not express tuberin and LOH was
not detected. This inability to find a deletion of TSC2
locus in the newly isolated angiomyolipoma cells could
have been explained by a number of different possibili-
ties such as a second mutations, as shown for the PDK1
and PDK2 genes in autosomal-dominant polycystic kid-
ney disease,31 or the methylations of the wild-type allele
frequently observed in human cancers.32,33 In these
TSC2 ASM cells we detected a methylation of the CpG
island leading to the inhibition of tuberin expression. Thus
the methylated purified ASM cells were named TSC2/meth
ASM cells.
DNA methylation at CpG dinucleotides is a common
and important epigenetic mechanism of inactivation of
tumor suppressor in cancers, and such a genetic modi-
fication is performed by DNA methyltransferase.34 Sev-
eral human genes contain a CpG island within their
promoter region, and unmethylated CpG islands are gen-
erally protected from methylation in normal cells.35 How-
ever, the de novo methylation of CpG islands that over-
laps with promoter regions is a common feature in human
cancer, and results in the loss of gene function, similar to
other mechanisms such as deletion or point muta-
tion.33,36 The methylation of the TSC2 promoter is biolog-
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Figure 7. Effect of rapamycin (1 ng/ml) and anti-EGFR antibody (5 g/ml)
on phosphorylation of S6 (Ser235/236) and ERK in TSC2/meth ASM cells.
The blots are representative of three experiments. Incubation with rapamycin
inhibited constitutive S6 phosphorylation within 24 hours, whereas inhibition
of Erk (Thr202/Tyr204) phosphorylation required 48 hours. The effect of
anti-EGFR on Erk phosphorylation was superior to that of rapamycin. These
data were confirmed by the densitometric analysis. Mean values  SEM.
Significant differences (***P  0.001) versus control were evaluated by
Student’s t-test.
Figure 8. Exposure to rapamycin (1 and 5 ng/ml) added at plating time or
3 hours after plating failed to modify the expression of p21 and p53. The
levels of -actin were evaluated as protein control.
Table 1. Cell Proliferation Rate and Rapamycin Effect
Days 5 8 10
TSC2/meth ASM cells 180% 230% 286%
TSC2/meth ASM cells with
rapamycin 1 ng/ml at
plating time
143% 143% 125%
TSC2/meth ASM cells with
rapamycin 1 ng/ml 3
hours after plating
152% 160% 168%
TSC2/meth ASM cells with
rapamycin 5 ng/ml at
plating time
89% 89% 45%
TSC2/meth ASM cells with
rapamycin 5 ng/ml 3
hours after plating
116% 125% 45%
Percentage increase in cell number. We plated 2.8  104 cells and
the number of cells was evaluated at the indicated time.
Table 2. Effect of Rapamycin on Apoptosis
Percent of
TUNEL-positive cells
TSC2/meth ASM cells 4.5
TSC2/meth ASM cells  1 ng/ml
rapamycin at plating time
6.1
TSC2/meth ASM cells  5 ng/ml
rapamycin at plating time
6.9
TSC2/meth ASM cells  1 ng/ml
rapamycin 3 hours after plating
4.4
TSC2/meth ASM cells  5 ng/ml
rapamycin 3 hours after plating
5.2
VSMCs 5.1
VSMCs  staurosporin 57.3
Percentage of TUNEL-positive cells. Rapamycin was incubated for
10 days at the indicated conditions and TUNEL-positive and -negative
cells were counted. VSMCs were incubated with 100 mmol/L
staurosporin for 1 hour and 30 minutes.
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ically very relevant in the case of TSC2/meth ASM cells
because the functional effect on tuberin transcription is a
complete blockade because of the present germline mu-
tation of TSC2 intron 8-exon 9 junction on the other allele.
In a previous report no evidence of methylation within
TSC2 promoter region of the wild-type allele was found in
hamartomas obtained from TSC patients.11 Failure to
demonstrate promoter methylation may be attributed to
heterogeneity of tumor tissues whereas in the case of
TSC2/meth ASM cells we analyzed a pure population. On
the other hand, there are several examples in cancer of
functional modification of TSC gene by methylation. One
is the clinical outcome of patients with breast cancer,
that turns unfavorable, where the TSC promoter is
methylated.37 Also the down-regulation of TSC gene
function in oral squamous cell carcinoma can be as-
cribed to an epigenetic alteration by methylation of the
TSC promoter.38
The role of promoter methylation of the wild-type allele,
in the abnormal development of TSC2/meth cells is con-
firmed by the normalizing effects of chromatin-remodel-
ing agents, trichostatin A and 5-azacytidine. These
agents promoted the expression of tuberin and down-
regulated the constitutive phosphorylation of S6 and the
labeling by HMB45 antibody. Histone deacetylase
(HDAC) inhibitors, such as trichostatin A, are a new class
of targeted anticancer agents, which are potent inducers
of cellular differentiation, growth arrest, and cell death,
and are effective in vitro and in vivo.39 By reversible acet-
ylation, HDAC inhibitors modify the structure and function
of histones and proteins in transcription factor com-
plexes, which are involved in the regulation of gene ex-
pression. The inhibition of the HDAC could increase the
remission rate of many kinds of solid tumors, obviously
by cooperation with other anticancer drugs.40 It is thus,
conceivable that, in cases such as this, the use of
HDAC inhibitors may result in an important additional
therapeutic approach to the treatments for TSC now in
development.18,41
As described for TSC2/ ASM cells,18 TSC2/meth
ASM cell growth required the addition of EGF in the
growth medium, and the exposure to anti-EGFR antibody
caused the blockade of cell proliferation and, then,
death. The growth rate of the two types of TSC2 cells is
similar, thus the lack of tuberin, resulted from two different
genetic lesions, leads to EGF dependence in both cases.
The EGFR signaling pathways regulate cell differentia-
tion, proliferation, and migration and, in the case of TSC2
cells, might also be involved in the constitutive S6 phos-
phorylation. Anti-EGFR antibody has been shown to be
efficacious in several types of cancer, such as colorectal
and head and neck cancers42 and we suggest that might
be also of therapeutic value in TSC.18
Rapamycin, a mTOR inhibitor, has been identified as a
potential therapeutic agent for TSC and LAM43,44 and a
recently reported clinical trial shows its potential efficacy
in promoting the regression of TSC angiomyolipomas.41
The exposure to rapamycin down-regulated the constitu-
tive S6 phosphorylation in TSC2/meth ASM cells and it
was capable of inhibiting cellular proliferation either when
added at plating time or in a delayed application. In
TSC2/ ASM cells, rapamycin regulated proliferation
only when added at plating time, and this is a clear
pharmacological difference with TSC2/meth ASM cells.18
The inhibitory effects of rapamycin on TSC2/meth
ASM cell proliferation did not require any activation of
apoptosis.
In addition to the proliferative effects caused by the
lack of tuberin, we observed that LY294002 failed to
inhibit IGF-1-mediated Akt phosphorylation in TSC2/meth
ASM cells. When trichostatin A was added to the growth
medium, the ability of LY294002 to inhibit IGF-1-mediated
and basal Akt phosphorylation was apparent. A similar
phenomenon was observed in TSC2/ ASM cells and
the introduction of the TSC2 gene restored the normal
pharmacological activity of this drug.26 Thus, in both
TSC2 cell types the lack of tuberin affects also the sen-
sitivity to drugs.
In conclusion, this study provides the first evidence
that the methylation of the TSC2 promoter as a second hit
may cause the blockade of tuberin expression and full
deployment of TSC2 cellular phenotype. The demethyl-
ation ability of an HDAC inhibitor, trichostatin A, and a
DNA methylase inhibitor, 5-azacytidine, allowed the ex-
pression of tuberin and reverted the biochemical, phar-
macological, and phenotypical characteristics. The
growth of these cells requires EGF in the medium, and
the blockade of EGFR leads to their death. These meth-
ylated cells, differently from TSC2/ ASM cells18 are
very sensitive to the cytostatic action of rapamycin.
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